Researchers have identified a disease mechanism that could be targeted to develop treatments for pulmonary arterial hypertension (PAH). In a rat model of PAH, a compound that reduces oxidative stress lowered pulmonary pressure and prevented remodeling of lung blood vessels. Oxidative stress is a major contributor to the events leading…
The U.S. Food and Drug Administration (FDA) accepted several modifications proposed by Bellerophon Therapeutics for its Phase 3 program to evaluate the efficacy and safety of INOpulse in patients with pulmonary arterial hypertension (PAH). Under the new testing program, INOpulse may be ready for FDA review and possible…
Eiger BioPharmaceuticals recently announced that a first patient has completed the 24-week dosing in the Phase 2 LIBERTY study assessing ubenimex as a therapy for pulmonary arterial hypertension (PAH). That patient is now continuing with treatment in an open-label extension trial. “There has been tremendous enthusiasm in the entire community — patients, families,…
A triple combination therapy with Tracleer (bosentan), Viagra (sildenafil), and Veletri (epoprostenol) can completely reverse right ventricular remodeling that occurs in pulmonary hypertension, according to a case study published in the medical journal Respiratory Medicine Case Reports.
Noninvasive methods can help to determine which patients have a high probability of developing pulmonary hypertension (PH) and which are most unlikely to do so, researchers reported — offering clinicians further tools when examining people with suspected lung hypertension. The study, “Use of ECG and Other Simple Non-Invasive Tools…
Statins added to pulmonary hypertension (PH) treatment do not provide any clinical benefit for a clear majority of patients — although this drug’s use in those whose PH is the result of chronic obstructive pulmonary disease (COPD) show some “intriguing” points worthy of further study, researchers…
A woman with the genetic disease neurofibromatosis type 1 (NF1) who developed pulmonary hypertension (PH) was successfully treated with a combination of increased pulmonary arterial hypertension (PAH)-specific therapy and surgery that created a hole between her two heart chambers. The study, “Atrial septostomy and disease targeting…
Iron deficiency or low iron levels do not seem to be associated with pulmonary hypertension (PH), a study published in the scientific journal Plos One suggests.
SteadyMed Therapeutics, a California-based specialty pharmaceutical company that develops drug products for treating orphan and high-value diseases with unmet non-oral delivery needs, has hired Carl Hicks, Jr. to take on the newly created role of Vice President of PH Patient Advocacy and Community Relations. Hicks is a 20-year…
A molecule linked to pulmonary hypertension (PH) in earlier studies failed to serve as a biomarker of disease severity or prognosis in a new study, which analyzed blood levels of the factor in people with various types of lung hypertension. Although the molecule, known as Ang-1, does not appear to be a…
Pharmacologically inhibiting an enzyme called tryptophan hydroxylase 1 (TPH1) that plays a role in serotonin biosynthesis can significantly reduce pulmonary arterial pressure, as well as pulmonary blood vessel wall thickness and blockade, according to a study published in the Journal of Pharmacology and Experimental Therapeutics.
A compilation of results from studies published from 2007–14 confirms that cardiac magnetic resonance (CMR) findings are useful in predicting outcomes in pulmonary arterial hypertension (PAH) patients and, in the future, may help in determining best therapies as the disease progresses. The review, “Cardiac…
Get regular updates to your inbox.
